Clinical results of hypomethylating agents in AML treatment

Journal of Clinical Medicine

Volumn 4, Issue 1, 2014, Pages

  Cruijsen, Marjan ^a   Lübbert, Michael ^b   Wijermans, Pierre ^c   Huls, Gerwin ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF FREIBURG   (Germany)

^c HAGA HOSPITAL   (Netherlands)

Author keywords

AML; Azacitidine; Decitabine; Elderly; Epigenetics; Hypomethylating agents

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; CYTARABINE; DNA METHYLTRANSFERASE INHIBITOR;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CHRONIC MYELOMONOCYTIC LEUKEMIA; CYTOGENETICS; CYTOTOXICITY; DISEASE FREE SURVIVAL; DRUG EFFICACY; EPIGENETICS; HUMAN; MULTICENTER STUDY (TOPIC); MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; SURVIVAL RATE;

EID: 84961411072     PISSN: None     EISSN: 20770383     Source Type: Journal    
DOI: 10.3390/jcm4010001     Document Type: Article

References (47)

1. Gronbaek, K.; Hother, C.; Jones, P.A. Epigenetic changes in cancer. APMIS 2007, 115, 1039–1059
2. Jones, P.; Baylin, S.B. The epigenomics of cancer. Cell 2007, 128, 683–692
3. Figueroa, M.E.; Skrabanek, L.; Li, Y.; Jiemjit, A.; Fandy, T.E.; Paietta, E.; Fernandez, H.; Tallman, M.S.; Greally, J.M.; Carraway, H., et al. MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood 2009, 114, 3448–3458
4. Figueroa, M.E.; Lugthart S.; Li, Y.; Erpelinck-Verschueren, C.; Deng, X.; Christos, P.J.; Schifano, E.; Booth, J.; van Putten, W.; Skrabanek, L., et al. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell 2010, 17, 13–17
5. Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N. Engl. J. Med. 2013, 368, 2059–2074
6. Patel, J.P.; Gönen, M.; Figueroa, M.E.; Fernandez, H.; Sun Z.; Racevskis, J.; van Vlierberghe, P.; Dolgalev, I.; Thomas, S.; Aminova, O., et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N. Engl. J. Med. 2012, 366, 1079–1089
7. Jüttermann, R.; Li, E.; Jaenisch, R. Toxicity of 5-aza-2′-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. Proc. Natl. Acad. Sci. USA 1994, 91, 11797–11801
8. Goodyear, O.; Agathanggelou, A.; Novitzky-Basso, I.; Siddique, S.; McSkeane, T.; Ryan, G.; Vyas, P.; Cavenagh, J.; Stankovic, T.; Moss, P., et al. Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia. Blood 2010, 116, 1908–1918
9. Silverman, L.R.; Demakos, E.P.; Peterson, B.L.; Kornblith, A.B.; Holland, J.C.; Odchimar-Reissig, R.; Stone, R.M.; Nelson, D.; Powell, B.L.; DeCastro, C.M., et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B. J. Clin. Oncol. 2002, 20, 2429–2440
10. Fenaux, P.; Mufti, G.J.; Hellström-Lindberg, E.; Santini, V.; Finelli, C.; Giagounidis, A.; Schoch, R.; Gattermann, N.; Sanz, G.; List, A. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: A randomised, open-label, phase III study. Lancet Oncol. 2009, 10, 223–232
11. Silverman, L.R.; McKenzie, D.R.; Peterson, B.L.; Holland, J.F.; Backstrom, J.T.; Beach, C.L.; Larson, R.A. Cancer and Leukemia group B Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: Studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J. Clin. Oncol. 2006, 20, 3895–3903
12. Fenaux, P.; Mufti, G.J.; Hellström-Lindberg, E.; Santini, V.; Gattermann, N.; Germing, U.; Sanz, G.; List, A.F.; Gore, S.; Seymour, J.F., et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukaemia. J. Clin. Oncol. 2010, 28, 562–569
13. Dombret, H.; Seymour J.F.; Butrym, A.; Wierzbowska, A.; Selleslag, D.; Jang, J.H.; Kumar, R.; Cavenagh, J.; Schuh, A.; Candoni, A., et al. Results of a phase 3, multicenter, randomized, open-label study of azacitidine vs. conventional care regimens in older patients with newly diagnosed acute myeloid leukemia. In Proceedings of the 19th Congres of the European Hematology Association, Milan, Italy, 12–15 June 2014
14. Lübbert, M.; Rüter, B.H.; Claus, R.; Schmoor, C.; Schmid, M.; Germing, U.; Kuendgen, A.; Rethwisch, V.; Ganser, A.; Platzbecker, U., et al. A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy. Haematologica 2012, 97, 393–401
15. Kantarjian, H.; Oki, Y.; Garcia-Manero, G.; Huang, X.; O’Brien, S.; Cortes, J.; Faderl, S.; Bueso-Ramos, C.; Ravandi, F.; Estrov, Z. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2007, 109, 52–57
16. Blum, W.; Garzon, R.; Klisovic, R.B.; Schwind, S.; Walker, A.; Geyer, S.; Liu, S.; Havelange, V.; Becker, H.; Schaaf, L., et al. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc. Natl. Acad. Sci. USA 2010, 107, 7473–7478
17. Ritchie, E.K.; Feldman, E.J.; Christos, P.J.; Rohan, S.D.; Lagassa, C.B.; Ippoliti, C.; Scandura, J.M.; Carlson, K.; Roboz, G.J. Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia. Leuk. Lymphoma 2013, 54, 2003–2007
18. Steensma, D.P.; Baer, M.R.; Slack, J.L.; Buckstein, R.; Godley, L.A.; Garcia-Manero, G.; Albitar, M.; Larsen, J.S.; Arora, S.; Cullen, M.T., et al. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: The alternative dosing for outpatient treatment (ADOPT) trial. J. Clin. Oncol. 2009, 27, 3842–3848
19. Kantarjian, H.M.; Thomas, X.G.; Dmoszynska, A.; Wierzbowska, A.; Mazur, G.; Mayer, J.; Gau, J.P.; Chou, W.C.; Buckstein, R.; Cermak, J., et al. Multicenter, randomized, open-label, phase III trial of decitabine vs. patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J. Clin. Oncol. 2012, 30, 2670–2677
20. Prebet, T.; Sun, Z.; Figueroa, M.E.; Ketterling, R.; Melnick, A.; Greenberg, P.L.; Herman, J.; Juckett, M.; Smith, M.R.; Malick, L., et al. Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: Results of the US Leukemia Intergroup trial E1905. J. Clin. Oncol. 2014, 32, 1242–1248
21. Löwenberg, B.; Ossenkoppele, G.J.; van Putten, W.; Schouten, H.C.; Graux, C.; Ferrant, A.; Sonneveld, P.; Maertens, J.; Jongen-Lavrencic, M.; von Lilienfeld-Toal, M., et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N. Engl. J. Med. 2009, 361, 1235–1248
22. Grövdal, M.; Karimi, M.; Khan, R.; Aggerholm, A.; Antunovic, P.; Astermark, J.; Bernell, P.; Engström, L.M.; Kjeldsen, L.; Linder, O., et al. Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy. Br. J. Haematol. 2010, 150, 293–302
23. Boumber, Y.; Kantarjian, H.; Jorgensen, J.; Wen, S.; Faderl, S.; Castoro, R.; Autry, J.; Garcia-Manero, G.; Borthakur, G.; Jabbour, E., et al. A randomized study of decitabine vs. conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission. Leukemia 2012, 26, 2428–2431
24. Lübbert, M.; Bertz, H.; Müller, M.J.; Finke, J. When azanucleoside treatment can be curative: Nonintensive bridging strategy before allografting in older patients with myelodysplastic syndrome/acute myeloid leukemia. J. Clin. Oncol. 2013, 31, 822–823
25. De Padua Silva, L.; de Lima, M.; Kantarjian, H.; Faderl, S.; Kebriaei, P.; Giralt, S.; Davisson, J.; Garcia-Manero, G.; Champlin, R.; Issa, J.P., et al. Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome. Bone Marrow Transpl. 2009, 43, 839–843
26. Lübbert, M.; Bertz, H.; Rüter, B.; Marks, R.; Claus, R.; Wäsch, R.; Finke, J. Non-intensive treatment with low-dose 5-aza-2′-deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS/AML patients. Bone Marrow Transpl. 2009, 44, 585–588
27. Cogle, C.R.; Imanirad, I.; Wiggins, L.E.; Hsu, J.; Brown, R.; Scornik, J.C.; Wingard, J.R. Hypomethylating agent induction therapy followed by hematopoietic cell transplantation is feasible in patients with myelodysplastic syndromes. Clin. Adv. Hematol. Oncol. 2010, 8, 40–46
28. Field, T.; Perkins, J.; Huang, Y.; Kharfan-Dabaja, M.A.; Alsina, M.; Ayala, E.; Fernandez, H.F.; Janssen, W.; Lancet, J.; Perez, L., et al. 5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation. Bone Marrow Transpl. 2010, 45, 255–260
29. Kim, D.Y.; Lee, J.H.; Park, Y.H.; Lee, J.H.; Kim, S.D.; Choi, Y.; Lee, S.B.; Lee, K.H.; Ahn, S.Y.; Lee, Y.S., et al. Feasibility of hypomethylating agents followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome. Bone Marrow Transpl. 2012, 47, 374–379
30. Gerds, A.T.; Gooley, T.A.; Estey, E.H.; Appelbaum, F.R.; Deeg, H.J.; Scott, B.L. Pretransplantation therapy with azacitidine vs. induction chemotherapy and posttransplantation outcome in patients with MDS. Biol. Blood Marrow Transpl. 2012, 18, 1211–1218
31. Damaj, G.; Duhamel, A.; Robin, M.; Beguin, Y.; Michallet, M.; Mohty, M.; Vigouroux, S.; Bories, P.; Garnier, A.; el Cheikh, J., et al. Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: A study by the Société Française de Greffe de Moelle et de Thérapie-Cellulaire and the Groupe-Francophone des Myélodysplasies. J. Clin. Oncol. 2012, 30, 4533–4540
32. Platzbecker, U.; Schetelig, J.; Finke, J.; Trenschel, R.; Scott, B.; Kobbe, G.; Schaefer-Eckart, K.; Bornhäuser, M.; Itzykson, R.; Germing, U. Allogeneic hematopoietic cell transplantation in patients age 60–70 years with de novo high-risk myelodysplastic syndrome or secondary acute myelogenous leukemia: Comparison with patients lacking donors who received azacitidine. Biol. Blood Marrow Transpl. 2012, 18, 1415–1421
33. De lima, M.; Giralt, S.; Thall, P.; de Padua Silva, L.; Jones, R.; Komanduri, K.; Braun, T.; Nguyen, H.; Champlin, R.; Garcia-Manero, G. Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: A dose and schedule finding study. Cancer 2010, 116, 5420–5431
34. Platzbecker, U.; Wermke, M.; Radke, J.; Oelschlaegel, U.; Seltman, F.; Kiani, A.; Klut, I.; Knoth, H.; Röllig, C.; Schetelig, J., et al. Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: Results of the RELAZA trial. Leukemia 2012, 26, 381–389
35. Jabbour, E.; Giralt, S.; Kantarjian, H.; Garcia-Manero, G.; Jagasia, M.; Kebriaei, P.; de Padua, L.; Shpall, E.; Champlin, R.; de Lima, M. Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia. Cancer 2009, 115, 1899–1905
36. Lübbert, M.; Bertz, H.; Wäsch, R.; Marks, R.; Rüter, B.; Claus, R.; Finke, J. Efficacy of a 3-day, low-dose treatment with 5-azacytidine followed by donor lymphocyte infusions in older patients with acute myeloid leukemia or chronic myelomonocytic leukemia relapsed after allografting. Bone Marrow Transpl. 2010, 45, 627–632
37. Schroeder, T.; Czibere, A.; Platzbecker, U.; Bug, U.; Uharek, L, Luft, T.; Giagounidis, A.; Zohren, F.; Bruns, I.; Wolschke, C., et al. Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation. Leukemia 2013, 27, 1229–1235
38. Burnett, A.; Wetzler, M.; Löwenberg, B. Therapeutic advances in acute myeloid leukemia. J. Clin. Oncol. 2011, 29, 487–94
39. Löwenberg, B.; Zittoun, R.; Kerkhofs, H.; Jehn, U.; Abels, J.; Debusscher, L.; Cauchie, C.; Peetermans, M.; Solbu, G.; Suciu, S. On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukaemia: A randomized phase III study of the european organization for research and treatment of cancer leukaemia group. J. Clin. Oncol. 1989, 7, 1268–1274
40. Juliusson, G.; Antunovic, P.; Derolf, A.; Lehmann, S.; Mollgard, L.; Stockelberg, D.; Tidefelt, U.; Wahlin, A.; Hoglund, M. Age and acute myeloid leukaemia: Real world data on decision to treat and outcomes from the swedish acute leukaemia registry. Blood 2009, 113, 4179–4187
41. Tilly, H.; Castaigne, S.; Bordessoule, D.; Casassus, P.; le Prise, P.Y.; Tertian, G.; Desablens, B.; Henry-Amar, M.; Degos, L. Low-dose cytarabine vs. intensive chemotherapy in the treatment of acute nonlymphocytic leukaemia in the elderly. J. Clin. Oncol. 1990, 8, 272–279
42. Burnett, A.K.; Milligan, D.; Prentice, A.G.; Goldstone, A.H.; McMullin, M.F.; Hills, R.K.; Wheatley, K. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukaemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer 2007, 109, 1114–1124
43. Quintas-Cardama, A.; Ravandi, F.; Liu-Dumlao, T.; Brandt, M.; Faderl, S.; Pierce, S.; Borthakur, G.; Garcia-Manero, G.; Cortes, J.; Kantarjian, H. Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia. Blood 2012, 120, 4850–4855
44. Van der Helm, L.H.; Scheepers, E.R.; Veeger, N.J.; Daenen, S.M.; Mulder, A.B.; van den Berg, E.; Vellenga, E.; Huls, G. Azacitidine might be beneficial in a subgroup of older AML patients compared to intensive chemotherapy: A single centre retrospective study of 227 consecutive patients. J. Hematol. Oncol. 2013, 16, doi:10.1186/1756-8722-6-29
45. Van der Helm, L.; Alhan, C.; Wijermans, P.W.; van Marwijk Kooy, M.; Schaafsma, R.; Biemond, B.J.; Beeker, A.; Hoogendoorn, M.; van Rees, B.; de Weerdt, O., et al. Platelet doubling after the first azacitidine cycle is a promising predictor for response in MDS, CMML and AML patients in the Dutch azacitidine compassionate named patient program. Br. J. Haematol. 2011, 155, 599–606
46. Klepin, H.D.; Rao, A.V.; Pardee, T.S. Acute myeloid leukemia and myelodysplastic syndromes in older adults. J. Clin. Oncol. 2014, doi:10.1200/JCO.2014.55.1564
47. Giles, F.J.; Borthakur, G.; Ravandi, F.; Faderl, S.; Verstovsek, S.; Thomas, D.; Wierda, W.; Ferrajoli, A.; Kornblau, S.; Pierce, S., et al. The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia. Br. J. Haematol. 2007, 136, 624–627.